DoW Prostate Cancer, Physician Research Award

The Prostate Cancer Physician Research Award is administered by the Defense Health Agency through the Congressionally Directed Medical Research Programs as part of the broader Prostate Cancer Research Program. This initiative reflects a long-standing federal investment in advancing prostate cancer research, with congressional appropriations supporting innovative and high-impact studies since 1997. The award specifically aims to cultivate the next generation of physician-scientists by providing mentored research opportunities that align clinical practice with scientific investigation. The program is structured to address critical challenges in prostate cancer, particularly those that improve patient outcomes, quality of life, and survival. The primary purpose of this award is to support early-career physician investigators who are either completing their medical training or are within five years of their first faculty appointment. These individuals must maintain clinical responsibilities while pursuing research that addresses one of several defined overarching challenges, including improving survivorship, developing treatments for lethal prostate cancer, enhancing clinical care, or understanding disease progression. The award emphasizes both the scientific merit of the proposed research and the professional development of the principal investigator, ensuring that recipients gain the skills and experience necessary for long-term careers in prostate cancer research. Funding under this opportunity is substantial, with a total program allocation of approximately 8.8 million dollars expected to support around eight awards. Each award is capped at 1.1 million dollars in total costs over a maximum performance period of four years. Funds may be used for a variety of research-related expenses, including clinical research costs and limited travel for collaboration or dissemination of findings. However, certain costs are explicitly restricted, such as clinical trial expenses, equipment purchases, and salary support for mentors or senior personnel other than the principal investigator. Cost sharing is not required, which lowers barriers to participation for eligible institutions. Eligibility for this program is broad at the organizational level, including both domestic and international institutions across public, private, nonprofit, and for-profit sectors. However, the principal investigator must meet strict early-career criteria and demonstrate a commitment to a physician-scientist career path. A key requirement of the program is the inclusion of at least one experienced mentor with a strong track record in prostate cancer research and mentorship. Applications must also include a detailed researcher development plan outlining how the investigator will acquire necessary skills and advance toward independence. The application process follows a two-step submission model. Applicants must first submit a pre-application in the form of a letter of intent through the Electronic Biomedical Research Application Portal. This is followed by a full application submitted through either Grants.gov or eBRAP, depending on the organization type. The full application requires extensive documentation, including a project narrative, technical and lay abstracts, a statement of work, a researcher development plan, and multiple supporting documents such as letters of support and data sharing plans. The process is highly structured and requires strict adherence to formatting and submission guidelines. Applications undergo a two-tier review process consisting of peer review and programmatic review. Peer review evaluates scientific merit, investigator potential, mentorship quality, research feasibility, and impact, while programmatic review considers alignment with program priorities and overall portfolio balance. The review criteria emphasize both the innovation and feasibility of the research as well as the career development trajectory of the principal investigator. Successful applicants are typically notified within weeks following programmatic review, with awards issued no later than September 30, 2027. Key deadlines for this funding opportunity include a pre-application submission deadline of August 12, 2026, and a full application deadline of September 2, 2026. Peer review is scheduled for November 2026, followed by programmatic review in March 2027. Awards are expected to be finalized within the same fiscal cycle. Support resources are available through eBRAP and Grants.gov help desks to assist applicants throughout the submission process. This funding opportunity is offered on an annual basis as part of the broader Prostate Cancer Research Program, reflecting an ongoing federal commitment to advancing research and improving outcomes for individuals affected by prostate cancer.

Emphasize strong mentorship and a clear researcher development plan; align research with one overarching challenge; demonstrate feasibility and impact; ensure compliance with all formatting and submission requirements